

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000548

International filing date: 16 February 2005 (16.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0403819.6
Filing date: 20 February 2004 (20.02.2004)

Date of receipt at the International Bureau: 07 April 2005 (07.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



PCT/GB 2005 / 0 0 0 5 4 8



INVESTOR IN PEOPLE


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Andrew Gersey

Signed

Dated 18 March 2005




The Patent Office

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

T1655PV

20 FEB 2004

2. Patent application number
(The Patent Office will fill in this part)

0403819.6

23 FEB 04 08:50:25 1 002637
P01/7700 0.00-0403819.6 NONE

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

Patents ADP number (if you know it)

00597799001

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

New compounds

5. Name of your agent (if you have one)

Mr. J. Horgan

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Merck & Co., Inc.
European Patent Department
Terlings Park
Eastwick Road
Harlow
Essex CM20 2QR

Patents ADP number (if you know it)

07536832001

4448791001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority Application number
(if you know it)

Date of filing
(day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	0
Description	45
Claim(s)	0
Abstract	0
Drawing(s)	0




10. If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	-
Request for preliminary examination and search (Patents Form 9/77)	-
Request for substantive examination (Patents Form 10/77)	-
Any other documents (please specify)	-

11.

I/We request the grant of a patent on the basis of this application.

Signature



Mr. J. Horgan

Date 20 February 2004

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr. J. Horgan

01279 440625

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

NEW COMPOUNDS

The present invention is concerned with prodrugs of substituted amino-heterocycles and pharmaceutically acceptable salts thereof which are useful as
5 therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1). The prodrugs of this invention have surprising superior physicochemical properties enabling much more drug to be bioavailable.


The pharmacologically active ingredient of chilli peppers has been recognised
10 for some time to be the phenolic amide capsaicin. The application of capsaicin to mucous membranes or when injected intradermally, causes intense burning-like pain in humans. The beneficial effects of topical administration of capsaicin as an analgesic is also well established. However, understanding of the underlying molecular pharmacology mediating these responses to capsaicin has been a more
15 recent development.

The receptor for capsaicin, termed the vanilloid VR1 receptor, was cloned by Caterina and colleagues at UCSF in 1997 (*Nature*, 398:816, 1997). VR1 receptors are cation channels that are found on sensory nerves that innervate the skin, viscera, peripheral tissues and spinal cord. Activation of VR1 elicits action potentials in
20 sensory fibres that ultimately generate the sensation of pain. Importantly VR1 receptor is activated not only by capsaicin but also by acidic pH and by noxious heat stimuli. It is also sensitized by a number of inflammatory mediators and thus appears to be a polymodal integrator of painful stimuli.

The prototypical VR1 antagonist is capsazepine (Walpole *et al.*,
25 *J. Med. Chem.*, 37:1942, 1994) – VR1 IC₅₀ of 420nM. A novel series of sub-micromolar antagonists has also been reported recently (Lee *et al.*, *Bioorg. Med. Chem.*, 9:1713, 2001), but these reports provide no evidence for *in vivo* efficacy. A much higher affinity antagonist has been derived from the 'ultra-potent' agonist resiniferatoxin. Iodo-resiniferatoxin (Wahl *et al.*, *Mol. Pharmacol.*, 59:9,
30 2001) is a nanomolar antagonist of VR1 but does not possess properties suitable for an oral pharmaceutical. This last is also true of the micromolar peptoid antagonists described by Garcia-Martinez (*Proc. Natl. Acad. Sci., USA*, 99:2374, 2002). Most recently International (PCT) patent publication No. WO 02/08221 has described a

novel series of VR1 antagonists, which are stated to show efficacy in a number of animal models. We herein describe another novel series of VR1 modulators. These comprise predominantly VR1 antagonists but encompass VR1 partial antagonists and VR1 partial agonists. Such compounds have been shown to be efficacious in animal models of pain.

The present invention provides compounds of formula (I):



wherein:

one of T¹ and T⁴ is N and the other is C;

one of T² and T³ is N and the other is C(CH₂)_nR² or N;

X, Y and Z are independently N or C(CH₂)_nR³;

R¹ is Ar¹ or R¹ is C₁₋₆alkyl optionally substituted with one or two groups Ar¹;

Ar¹ is cyclohexyl, piperidiny, piperaziny, morpholiny, adamantyl, phenyl, naphthyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms, a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one O or S atom being present, or a nine- or ten-membered bicyclic heteroaromatic ring in which phenyl or a six-membered heteroaromatic ring as defined above is fused to a six- or five-membered heteroaromatic ring as defined above;

Ar¹ is optionally substituted by one, two or three groups chosen from halogen, hydroxy, cyano, nitro, isonitrile, CF₃, OCF₃, SF₅, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylsulfinyl, C₁₋₆alkylsulfonyl, -NR⁶R⁷, CONR⁶R⁷, -COH, -CO₂H, C₁₋₆alkylcarbonyl, C₁₋₆alkoxycarbonyl, haloC₁₋₆alkyl, haloC₂₋₆alkenyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₃₋₆cycloalkyl,

hydroxyC₃₋₆cycloalkyl, aminoC₃₋₆cycloalkyl, haloC₃₋₆cycloalkyl, cyanoC₃₋₆cycloalkyl, haloC₁₋₆alkylcarbonyl, C₁₋₆alkoxycarbonylC₁₋₆alkyl, (halo)(hydroxy)C₁₋₆alkyl, (halo)(hydroxy)C₃₋₆cycloalkyl, phenyl and a five-membered heteroaromatic ring containing one, two or three heteroatoms, at most one O or S atom being present;

5 wherein the phenyl and five-membered heteroaromatic ring are optionally substituted by C₁₋₆alkyl, halo, hydroxy or cyano; when two C₁₋₆alkyl groups substitute adjacent positions on Ar¹ then, together with the carbon atoms to which they are attached, they may form a partially saturated ring containing five or six carbon atoms; when two C₁₋₆alkoxy groups substitute adjacent positions on Ar¹ then, together with the carbon

10 atoms to which they are attached, they may form a partially saturated five- or six-membered ring;

Ar is phenyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms or a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, Ar

15 being optionally substituted by one, two or three groups chosen from halogen, CF₃, OCF₃, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, nitro, cyano, isonitrile, hydroxy, C₁₋₆alkoxy, C₁₋₆alkylthio, -NR⁶R⁷, -CONR⁶R⁷, -COH, CO₂H, C₁₋₆alkoxycarbonyl, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, C₁₋₆alkylcarbonyl and a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N

20 and S, at most one heteroatom being O or S, optionally substituted by C₁₋₆alkyl, halogen, amino, hydroxy or cyano;

R² and R³ are independently hydrogen, halogen, CF₃, OCF₃, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, nitro, cyano, isonitrile, hydroxy, C₁₋₆alkoxy, C₁₋₆alkylthio, -NR⁶R⁷, -CONR⁶R⁷, -COH, CO₂H, C₁₋₆alkoxycarbonyl, haloC₁₋₆alkyl,

25 hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, C₁₋₆alkylaminoC₁₋₆alkyl, di(C₁₋₆alkyl)aminoC₁₋₆alkyl, amido, piperidinyl, piperazinyl, C₃₋₆cycloalkyl, morpholinyl, phenyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms or a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one O or S atom being present,

30 which phenyl, six-membered heteroaromatic ring and five-membered heteroaromatic ring are optionally substituted by haloC₁₋₆alkyl, C₁₋₆alkyl, hydroxy, halogen, amino or cyano;

R^6 and R^7 are independently hydrogen or C_{1-6} alkyl; when both R^6 and R^7 are C_{1-6} alkyl then, together with the nitrogen atom to which they are attached, they may form a five or six membered saturated nitrogen containing ring;

n is zero, one, two or three;

- 5 R^{10} and R^{11} are independently hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-6} cycloalkyl or $NR^{12}R^{13}$;

R^{12} and R^{13} are independently hydrogen or C_{1-6} alkyl or R^{12} and R^{13} , together with the nitrogen atom to which they are attached, may form a nitrogen containing heterocycle; and

- 10 A^- is a pharmaceutically acceptable anion.

Preferred core structures are obtained when Y is $C(CH_2)_nR^3$. In this case it is generally preferred that: X is N , Z is $C(CH_2)_nR^3$, T^4 is N , T^2 and T^3 are N or T^2 is $C(CH_2)_nR^2$ and T^3 is N or T^2 is N and T^3 is $C(CH_2)_nR^2$; or X and Z are $C(CH_2)_nR^3$ and T^2 , T^3 and T^4 are N ; or X is N , Z is $C(CH_2)_nR^3$, T^3 is $C(CH_2)_nR^2$ and T^2 and T^1 are N ; or X , Z , T^2 , T^3 and T^4 are N . Additional core structures include those where X and Z are N , T^2 and T^4 are N and T^3 is $C(CH_2)_nR^2$; or X and Z are $C(CH_2)_nR^3$, T^2 and T^4 are N and T^3 is $C(CH_2)_nR^2$; or X is $C(CH_2)_nR^3$, Z is N , T^3 and T^4 are N and T^2 is $C(CH_2)_nR^2$.

- 20 R^1 is preferably Ar^1 or C_{1-4} alkyl, especially C_{1-2} alkyl, substituted by one or two, preferably one, Ar^1 groups. In particular R^1 can be Ar^1 . R^1 may be butyl. R^1 may be cyclohexyl, piperidinyl or adamantyl.

- Ar^1 is preferably phenyl, isoquinolyl, piperidinyl, piperazinyl, morpholinyl, cyclohexyl, a six-membered heteroaromatic ring as defined above, such as pyridinyl, or adamantyl, unsubstituted or substituted with one two or three substituents as defined above. Thus Ar^1 may be phenyl, pyridinyl, piperidinyl, butyl, adamantyl or cyclohexyl. In particular, substituents are chosen from halogen, hydroxy, cyano, CF_3 , SF_5 , OCF_3 , C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, $-NR^6R^7$, cyano C_{1-4} alkyl, halo C_{1-4} alkylcarbonyl, C_{1-4} alkylcarbonyl, C_{1-4} alkoxycarbonyl, halo C_{1-4} alkyl, halo C_{2-4} alkenyl, hydroxy C_{1-4} alkyl, C_{3-6} cycloalkyl, cyano C_{3-6} cycloalkyl, (halo)(hydroxy) C_{1-4} alkyl, C_{1-4} alkoxycarbonyl C_{1-4} alkyl, phenyl, or a five-membered heteroaromatic ring as defined above where the phenyl or five-membered heteroaromatic ring is unsubstituted or substituted by C_{1-4} alkyl or halogen. More preferably the substituents
- 30

are chosen from CF_3 , OCF_3 , SF_5 , halogen, C_{1-4} alkyl, C_{1-4} alkoxy, $-\text{NR}^6\text{R}^7$, C_{1-4} alkylsulfonyl, cyano C_{1-4} alkyl, cyano C_{3-6} cycloalkyl, C_{1-4} alkylpyrazole, halophenyl, halo C_{1-4} alkylcarbonyl, phenyl, C_{1-4} alkoxycarbonyl C_{1-4} alkyl, C_{3-6} cycloalkyl, (halo)(hydroxy) C_{1-4} alkyl, hydroxy C_{1-4} alkyl, halo C_{1-4} alkyl and C_{1-4} alkylcarbonyl.

- 5 Thus the substituents can be chosen from CF_3 , OCF_3 , SF_5 , methyl, tertiarybutyl, fluorine, chlorine, methoxy, isopropyl, methylthio, hydroxymethyl, methylsulfonyl, acetyl, 1-trifluoromethylethen-1-yl, 2-cyanoprop-2-yl, 1-cyanocycloprop-1-yl, bromine, 2-methylpyrazol-3-yl, 4-fluorophenyl, trifluoromethylcarbonyl, phenyl, 1-ethoxycarbonyl-1-methylethyl, cyclohexyl, 1-hydroxy-1-trifluoromethyl-2,2,2-
10 trifluoroethyl, 1-hydroxy-2-methyl-2-propyl, cyano, ethoxycarbonyl, $-\text{OCH}_2\text{O}-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$ and dimethylamino.

- Thus Ar^1 may be phenyl, naphthyl, isoquinolinyl or pyridyl, particularly phenyl or pyridyl, especially phenyl. In particular Ar^1 may be unsubstituted or substituted with one or two substituents. Ar^1 may be unsubstituted. Ar^1 may be
15 substituted.

- Thus preferred R^1 groups include 4-trifluoromethylphenyl, 4-tertiarybutylphenyl, phenyl, 2-trifluoromethylphenyl, 3-chlorophenyl, 3-trifluoromethylphenyl, 2,4-difluorophenyl, 4-methoxyphenyl, 2-isopropylphenyl, 3-methylthiophenyl, 2-naphthyl, 4-trifluoromethoxyphenyl, 1,3-benzodioxol-5-yl, 20 2-cyanophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 4-dimethylaminophenyl, 2-methyl-4-chlorophenyl, 3-chloro-4-fluorophenyl, 2-fluoro-6-trifluoromethylphenyl, 2-trifluoromethyl-4-fluorophenyl, 3-trifluoromethyl-4-fluorophenyl, 2-chloro-4-trifluoromethylphenyl, 2,3-dihydro-1H-inden-5-yl, 2,3-dihydro-1,4-benzodioxin-6-yl, 5-isoquinolyl, 2-trifluoromethylpyridin-6-yl and 3-trifluoromethylpyridin-6-yl.

- 25 Further preferred R^1 groups include 2-phenylethyl, 3-fluorophenylmethyl, diphenylmethyl, (1S)-1-phenylethyl and 3,4-dichlorophenylmethyl.

- Yet further preferred R^1 groups include 4-fluorophenyl, 4-acetylphenyl, 4-methylthiophenyl, 1-trifluoromethylethen-1-ylphenyl, 4-(pentafluorothio)phenyl, 4-chlorophenyl, 4-methylphenyl, 4-hydroxymethylphenyl, 4-methylsulfonylphenyl, 30 2-chloropyrid-5-yl, 4-(1-cyano-1-methylethyl)phenyl, 4-(1-cyano-1-cyclopropyl)phenyl, 4-bromophenyl, 4-(2-methylpyrazol-3-yl)phenyl, 4-(4-fluorophenyl)phenyl, butyl, adamant-1-yl, 1-trifluoroacetyl-4-piperidinyl, cyclohexyl, 1-phenylpiperidin-4-yl, 4-isopropylphenyl, 4-(1-ethoxycarbonyl-1-

methylethyl)phenyl, 4-cyclohexylphenyl, 4-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoroethyl)phenyl, 4-(1-hydroxy-2-methyl-2-propyl)phenyl, 4-trifluoromethylphenylethyl, 4-cyanophenyl, 4-tert.butylcyclohexyl, 1-ethoxycarbonylpiperidin-4-yl, 3-methylpyridin-6-yl, 2-trifluoromethylpyridin-4-yl, 2-fluoro-4-trifluoromethylphenyl, 4-trifluoromethoxyphenyl and 3-fluoro-4-trifluoromethylphenyl. R^1 can be 4-trifluoromethylphenyl.

Ar is preferably phenyl or a 5- or 6-membered ring containing one or two nitrogen atoms. Ar is more preferably phenyl, pyridyl or imidazolyl, especially pyridyl such as pyrid-2-yl such as 3-substituted pyrid-2-yl. Ar may also be pyridazinyl.

Ar is preferably unsubstituted or substituted with one or two substituents. More particularly Ar is substituted with one substituent, particularly ortho to the point of attachment to the rest of the molecule.

The substituents on Ar are preferably chosen from halogen, CF_3 , OCF_3 , C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylcarbonyl, cyano, hydroxy C_{1-4} alkyl and a five-membered heteroaromatic ring as defined above, such as thiazolyl or pyrazolyl, optionally substituted by C_{1-4} alkyl, such as methyl.

The substituents on Ar are more preferably chosen from halogen, CF_3 , OCF_3 , C_{1-4} alkyl, C_{1-4} alkoxy, $-NR^6R^7$, halo C_{1-4} alkyl and amino C_{1-4} alkyl. More preferably they are chosen from halogen, CF_3 , C_{1-2} alkoxy and C_{1-2} alkyl, such as CF_3 , methyl and methoxy. Thus Ar can be 3-trifluoromethylpyrid-2-yl, 3-methylpyrid-2-yl, 3-methoxypyrid-2-yl, 4-trifluoromethylphenyl or 1-methylimidazol-2-yl. Ar can also be 3-chloropyrid-2-yl, 3-bromopyrid-2-yl, 3-(thiazol-2-yl)pyrid-2-yl, 3-(2-methylpyrazol-3-yl)pyrid-2-yl, 3-acetylpyrid-2-yl, 3-cyanopyrid-2-yl, 3-(2-hydroxyprop-2-yl)pyrid-2-yl, 4-methylpyridazin-3-yl, 4-trifluoromethylpyridazin-3-yl and 2-methoxyphenyl. Ar can be 3-trifluoromethylpyrid-2-yl.

R^2 is preferably hydrogen, halogen, CF_3 , C_{1-4} alkyl, C_{1-4} alkoxy, OCF_3 , $-NR^6R^7$, $-CO_2H$, cyano, amido, phenyl, pyridyl, morpholinyl, imidazolyl or C_{1-4} alkylimidazolyl. These groups may be joined to the rest of the molecule via an ethylene or methylene linker which, when present, is preferably methylene.

R^2 and R^3 are thus preferably hydrogen, halogen, CF_3 , C_{1-2} alkyl, C_{1-2} alkoxy, OCF_3 or $-NR^6R^7$. R^2 and R^3 are particularly hydrogen or halogen such as chlorine. R^2 and R^3 are generally hydrogen. Particular embodiments of R^2 are hydrogen, cyano,

bromine, 1-methylimidazol-2-yl, methyl, amido, phenyl, pyrid-4-yl, pyrid-3-yl, morpholin-4-ylmethyl, dimethylaminomethyl, imidazol-1-ylmethyl and carboxyl. R^3 may be hydrogen, halogen, such as bromine or chlorine, or cyano.

R^6 and R^7 are preferably hydrogen, methyl or ethyl. R^6 and R^7 can both be hydrogen, one can be hydrogen and the other can be methyl. In one embodiment they are both methyl.

n is generally 0, 1 or 2, preferably 0 or 1 and most often 0.

In a preferred embodiment T^4 is N and Y and Z are CR^3 . More preferably T^4 is N and Y and Z are CH.

For the avoidance of doubt the moiety $CH(R^{10})OC(O)R^{11}$ is always attached to a nitrogen atom.

A^- is preferably chloride.


R^{10} is preferably hydrogen or C_{1-4} alkyl such as methyl.

R^{11} is preferably C_{1-4} alkyl, C_{1-4} alkoxy or $NR^{12}R^{13}$.

R^{12} and R^{13} are preferably hydrogen or C_{1-4} alkyl or form, together with the nitrogen atom to which they are attached, a pyrrolidine ring.

Particular embodiments of R^{11} are 2-methylprop-2-yl, methyl, prop-2-yl, pyrrolidin-1-yl and 1-methylethoxyl.

Thus the present invention provides a class of compounds of formula I":



in which X is CH or N;

one of T^2 and T^3 is N and the other is $C(CH_2)_nR^2$;

R^2 is hydrogen, halogen, CF_3 , OCF_3 , C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, nitro, cyano, isonitrile, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, $-NR^6R^7$, $-CONR^6R^7$, $-COH$, CO_2H , C_{1-6} alkoxycarbonyl, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, amino C_{1-6} alkyl, C_{1-6} alkylamino C_{1-6} alkyl, di(C_{1-6} alkyl)amino C_{1-6} alkyl, amido, piperidiny, piperazinyl, C_{3-6} cycloalkyl, morpholinyl, phenyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms or a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one O or S atom being present, which phenyl, six-membered heteroaromatic ring and five-membered heteroaromatic ring are optionally substituted by halo C_{1-6} alkyl, C_{1-6} alkyl, hydroxy, halogen, amino or cyano;

R^6 and R^7 are independently hydrogen or C_{1-6} alkyl; when both R^6 and R^7 are C_{1-6} alkyl then, together with the nitrogen atom to which they are attached, they may form a five or six membered saturated nitrogen containing ring;

n is zero, one, two or three;

R^{10} and R^{11} are independently hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-6} cycloalkyl or $NR^{12}R^{13}$ where R^{12} and R^{13} are independently hydrogen or C_{1-6} alkyl or R^{12} and R^{13} , together with the nitrogen atom to which they are attached, form a nitrogen-containing heterocycle;

R^{14} and R^{15} are independently C_{1-6} alkyl, CF_3 , halo C_{1-6} alkyl, halogen, C_{1-6} alkoxy, halo C_{1-6} alkoxy or OCF_3 ; and

A^- is a pharmaceutically acceptable anion.

R^{10} is preferably hydrogen or C_{1-4} alkyl such as methyl.

R^{11} is preferably C_{1-4} alkyl, C_{1-4} alkoxy or $NR^{12}R^{13}$.

R^{12} and R^{13} are preferably hydrogen or C_{1-4} alkyl or form, together with the nitrogen atom to which they are attached, a pyrrolidine ring.


Particular embodiments of R^{11} are 2-methylprop-2-yl, methyl, prop-2-yl, pyrrolidin-1-yl and 1-methylethoxyl.

R^2 is preferably hydrogen, C_{1-6} alkyl or cyano. R^2 may be hydrogen.

R^{14} is preferably methyl, CF_3 or OCF_3 , particularly CF_3 .

R^{15} is preferably methyl, CF_3 or OCF_3 , particularly CF_3 .

The present invention also provides compounds of formula IA:




in which T^2 , T^3 , Ar, R^1 , R^{10} , R^{11} and A^- are as defined above. The preferred definitions of these substituents apply to this subgenus.

5 Compounds of formula IA are preferred in which R^2 is hydrogen, Ar is phenyl or pyridyl which is unsubstituted or substituted by methyl, CF_3 or methoxy and R^1 is phenyl substituted generally at the 4-position by CF_3 . More particularly Ar is pyridyl, such as pyrid-2-yl, substituted, preferably at the 3-position, by CF_3 .

The present invention also provides compounds of formula IB:

10




in which Ar, R^1 , R^3 , T^3 , R^{10} , R^{11} and A^- are as defined above for formula I including the preferences listed. In one embodiment of the compounds of formula IB, T^3 is N.

15 Compounds of formula IB are preferred in which Ar is pyridyl, particularly when substituted by hydroxy, methyl, methoxy or CF_3 , R^1 is phenyl, particularly when substituted by CF_3 , and R^3 is hydrogen or chlorine. Ar may be substituted by methyl, methoxy or CF_3 . Particular preference is for compounds where Ar is pyrid-2-yl substituted at the 3-position and R^1 is 4-trifluoromethylphenyl.


20

The present invention also provides compounds of formula IC:




in which Ar, R¹, R¹⁰, R¹¹ and A⁻ are as defined above for formula I including the preferences listed. Particularly preferred are compounds in which Ar is pyridyl, particularly when substituted by CF₃, and R¹ is phenyl, particularly when substituted by CF₃. Ar is generally pyrid-2-yl preferably substituted at the 3-position and R¹ is 4-trifluoromethylphenyl.

The present invention also provides compounds of formula ID:



in which Ar, R¹, T³, R¹⁰, R¹¹ and A⁻ are as defined above for formula I including the preferences listed. In one embodiment, T³ in the compounds of formula ID is N. Preferred are compounds in which Ar is pyridyl, particularly when substituted by CF₃ or Cl, and R¹ is phenyl, particularly when substituted by CF₃, cyano or chlorine. Particularly preferred are compounds in which Ar is pyridyl, particularly when substituted by CF₃, and R¹ is phenyl, particularly when substituted by CF₃. Ar is generally pyrid-2-yl preferably substituted at the 3-position and R¹ is 4-trifluoromethylphenyl. R¹ may be 4-chlorophenyl or 4-cyanophenyl.

The present invention provides compounds of formula IE:



- 5 in which Ar, R¹, R¹⁰, R¹¹ and A⁻ are as defined above for formula I including the preferences listed. Particularly preferred are compounds in which Ar is pyridyl, particularly when substituted by CF₃, and R¹ is phenyl, particularly when substituted by CF₃. Ar is generally pyrid-2-yl preferably substituted at the 3-position and R¹ is 4-trifluoromethylphenyl.
- 10 Particular embodiments of the invention include:
- 5-(2,2-dimethylpropanoyloxymethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride;
- 5-(1-(2,2-dimethylpropanoyloxy)-1-ethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride;
- 15 5-(1-acetoxy-1-ethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride;
- 5-(2-methylpropanoyloxymethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride;
- 5-(1-pyrrolidinylcarbonyloxymethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride;
- 20 5-(1-(2-methylpropanoyloxy)-1-ethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride;
- 5-(1-(1-methyl-1-ethoxycarbonyloxy)-1-ethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride;
- 25 1-{[2,2-dimethylpropanoyloxy]methyl}-3-{4-trifluoromethylphenylamino}-7-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-b]pyridazin-1-ium chloride; and

6-{{2,2-dimethylpropanoyloxy}methyl}-7-{4-trifluoromethylphenylamino}-3-[3-trifluoromethylpyridin-2-yl]imidazo[1,5-*b*]pyridazin-6-ium chloride.

Examples of compounds which can be converted to prodrugs according to the present invention include:

- 5 N-(4-trifluoromethylphenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-
b]pyridazine-3-amine;
N-(4-tert-butylphenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-
b]pyridazine-3-amine;
N-phenyl-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
- 10 N-[2-trifluoromethylphenyl]-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-
b]pyridazin-3-amine;
N-(3-chlorophenyl)-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-
3-amine;
N-[3-trifluoromethylphenyl]-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-
b]pyridazin-3-amine;
- 15 N-(2,4-difluorophenyl)-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-
b]pyridazin-3-amine;
N-[4-methoxyphenyl]-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-
b]pyridazin-3-amine;
- 20 N-[2-(1-methylethyl)phenyl]-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-
b]pyridazin-3-amine;
N-[3-methylsulfanylphenyl]-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-
b]pyridazin-3-amine;
N-(2-naphthalenyl)-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-
25 3-amine;
N-{4-trifluoromethoxyphenyl}-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-
b]pyridazin-3-amine;
N-(2-phenylethyl)-7-[3-trifluoromethyl-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-
amine;
- 30 N-(1,3-benzodioxol-5-yl)-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-
b]pyridazin-3-amine;
N-[3-fluorophenylmethyl]-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-
b]pyridazin-3-amine;

- 2-({7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-yl}amino)benzonitrile;
N-(diphenylmethyl)-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
- 5 N-[(1S)-1-phenylethyl]-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
N-(2,4-dichlorophenyl)-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
N-(3,4-dichlorophenyl)-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
- 10 N-[4-dimethylaminophenyl]-N-{7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-yl}amine;
N-[(3,4-dichlorophenyl)methyl]-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
- 15 N-(4-chloro-2-methylphenyl)-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
N-(3-chloro-4-fluorophenyl)-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
N-[2-fluoro-6-trifluoromethylphenyl]-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
- 20 N-[4-fluoro-2-trifluoromethylphenyl]-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
N-[4-fluoro-3-trifluoromethylphenyl]-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
- 25 N-[2-chloro-4-trifluoromethylphenyl]-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
N-(2,3-dihydro-1H-inden-5-yl)-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-[3-trifluoromethyl-2-pyridinyl][1,2,4]triazolo[4,3-b]pyridazin-3-amine;
- 30 N-(4-trifluoromethylphenyl)-7-(3-methyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;

- 5-chloro-7-(3-methyl-2-pyridyl)-N-(4-trifluoromethylphenyl)[1,2,4]triazolo[4,3-a]pyridin-3-amine;
- 5-chloro-7-(2-methoxyphenyl)-N-(4-trifluoromethylphenyl)[1,2,4]triazolo[4,3-a]pyridin-3-amine;
- 5 5-chloro-N-(4-trifluoromethylphenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-a]pyridin-3-amine;
- 6-chloro-N-(5-isoquinolyl)-7-(4-trifluoromethylphenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-amine;
- 7-(3-methyl-2-pyridyl)-N-(4-trifluoromethylphenyl)[1,2,4]triazolo[4,3-a]pyridin-3-amine;
- 10 7-(3-trifluoromethyl-2-pyridyl)-N-(4-trifluoromethylphenyl)[1,2,4]triazolo[4,3-a]pyridin-3-amine;
- 7-(2-methoxyphenyl)-N-(4-trifluoromethylphenyl)[1,2,4]triazolo[4,3-a]pyridin-3-amine;
- 15 N-(5-isoquinolyl)-7-(4-trifluoromethylphenyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- 7-(3-trifluoromethyl-2-pyridyl)-N-(5-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- N-(4-trifluoromethylphenyl)-6-(3-trifluoromethylpyrid-2-yl)pyrazolo[1,5-a]pyrimidin-3-amine;
- 20 4-trifluoromethylphenyl-3-(3-trifluoromethylpyridin-2-yl)imidazo[1,5-b]pyridazin-7-ylamine;
- N-[4-trifluoromethylphenyl]-7-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-b]pyridazin-3-amine;
- 25 7-[3-trifluoromethylpyridin-2-yl]-N-[5-trifluoromethylpyridin-2-yl]imidazo[1,2-b]pyridazin-3-amine;
- N-(5-methylpyridin-2-yl)-7-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-b]pyridazin-3-amine;
- [7-(3-methylpyridin-2-yl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl]-(4-trifluoromethylphenyl)amine; and
- 30 [7-(1-methyl-1H-imidazol-2-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]-(4-trifluoromethylphenyl)amine.

Further preferred compounds which can be converted to prodrugs of the invention include:

- 7-(3-chloro-2-pyridyl)-N-(4-trifluoromethylphenyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- 5 7-(3-bromo-2-pyridyl)-N-(4-trifluoromethylphenyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- 7-[3-(1,3-thiazol-2-yl)pyridin-2-yl]-N-(4-trifluoromethylphenyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- 7-[3-(1-methyl-1*H*-pyrazol-5-yl)pyridin-2-yl]-N-(4-trifluoromethylphenyl) [1,2,4]
- 10 triazolo[4,3-b]pyridazine-3-amine;
- 7-(3-ethoxycarbonyl-2-pyridyl)-N-(4-trifluoromethylphenyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- 7-(3-cyano-2-pyridyl)-N-4-trifluoromethylphenyl[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- 15 N-(4-chlorophenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- N-(4-tolyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- N-(4-(2-hydroxyethyl)phenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- 20 N-(4-methylsulfonylphenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- N-(2-chloro-5-pyridyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- N-(4-(1-cyano-1-methylethyl)phenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo
- 25 [4,3-b]pyridazine-3-amine;
- N-(4-(1-cyclopropylphenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- N-(4-bromophenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- 30 N-(4-(2-methyl-3-pyrazolo)phenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
- N-(4-(4-fluorophenyl)phenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;

- N-butyl-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
 N-(1-adamantyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
 N-(1-trifluoroacetyl-4-piperidiny)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo
 5 [4,3-b]pyridazine-3-amine;
 N-(1-cyclohexyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
 N-(1-phenyl-4-piperidiny)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
 10 N-(4-trifluoromethylphenyl)-7-(2-cyanophenyl)-[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
 N-(4-trifluoromethylphenyl)-7-(3-(1-hydroxy-1-methylethyl)-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
 N-(4-(1-methylethyl)phenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
 15 b]pyridazine-3-amine;
 N-(4-(1-ethoxycarbonyl-1-methylethyl)phenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
 N-(4-cyclohexylphenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
 20 N-(4-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoroethyl)phenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
 N-(4-(1-hydroxy-2-methyl-2-propyl)phenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
 N-(2-4-trifluoromethylphenylethyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]
 25 triazolo[4,3-b]pyridazine-3-amine;
 N-(trans)-(4-tert.-butylcyclohexyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
 N-(1-ethoxycarbonyl-4-piperidiny)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine;
 30 7-(4-methylpyridazin-3-yl)-N-[4-trifluoromethylphenyl][1,2,4]triazolo[4,3-b]pyridazine-3-amine;

- N-[4-trifluoromethylphenyl]-7-[5-trifluoromethylpyrimidin-4-yl][1,2,4]triazolo[4,3-
b]pyridazin-3-amine;
5-bromo-*N*-[4-trifluoromethylphenyl]-3-[3-trifluoromethylpyridin-2-yl]imidazo
[1,5-*b*]pyridazin-7-amine;
- 5 5-(1-methyl-1*H*-imidazol-2-yl)-*N*-[4-trifluoromethylphenyl]-3-[3-trifluoromethyl
pyridin-2-yl]imidazo[1,5-*b*]pyridazin-7-amine;
N-(4-chlorophenyl)-3-[3-trifluoromethylpyridin-2-yl]imidazo[1,5-*b*]pyridazin-7-
amine;
- 10 5-methyl-*N*-[4-trifluoromethylphenyl]-3-[3-trifluoromethylpyridin-2-yl]imidazo
[1,5-*b*]pyridazin-7-amine;
7-{[4-trifluoromethylphenyl]amino}-3-[3-trifluoromethylpyridin-2-yl]imidazo[1,5-
b]pyridazine-5-carbonitrile;
7-{[4-trifluoromethylphenyl]amino}-3-[3-trifluoromethylpyridin-2-yl]imidazo[1,5-
b]pyridazine-5-carboxamide;
- 15 3-(3-methylpyridin-2-yl)-*N*-[4-trifluoromethylphenyl]imidazo[1,5-*b*]pyridazin-7-
amine;
3-(3-methylpyridin-2-yl)-7-{[4-trifluoromethylphenyl]amino}imidazo[1,5-*b*]
pyridazine-5-carbonitrile;
5-phenyl-*N*-[4-trifluoromethylphenyl]-3-[3-trifluoromethylpyridin-2-yl]imidazo
- 20 [1,5-*b*]pyridazin-7-amine;
5-pyridin-4-yl-*N*-[4-trifluoromethylphenyl]-3-[3-trifluoromethylpyridin-2-
yl]imidazo[1,5-*b*]pyridazin-7-amine;
5-pyridin-3-yl-*N*-[4-trifluoromethylphenyl]-3-[3-trifluoromethylpyridin-2-
yl]imidazo[1,5-*b*]pyridazin-7-amine
- 25 5-(morpholin-4-ylmethyl)-*N*-[4-trifluoromethylphenyl]-3-[3-trifluoromethyl pyridin-
2-yl]imidazo[1,5-*b*]pyridazin-7-amine;
5-[dimethylaminomethyl]-*N*-[4-trifluoromethylphenyl]-3-[3-trifluoromethyl pyridin-
2-yl]imidazo[1,5-*b*]pyridazin-7-amine;
- 30 5-(1*H*-imidazol-1-ylmethyl)-*N*-[4-trifluoromethylphenyl]-3-[3-trifluoromethyl
pyridin-2-yl]imidazo[1,5-*b*]pyridazin-7-amine;
7-{[4-trifluoromethylphenyl]amino}-3-[3-trifluoromethylpyridin-2-yl]imidazo[1,5-
b]pyridazine-5-carboxylic acid;
7-[1-oxido-3-trifluoromethylpyridin-2-yl]-*N*-[4-trifluoromethylphenyl]-imidazo

- [1,2-*b*]pyridazin-3-amine;
 2-bromo-*N*-[4-trifluoromethylphenyl]-7-[3-trifluoromethylpyridin-2-yl]imidazo
 [1,2-*b*]pyridazin-3-amine;
 3-{{4-trifluoromethylphenyl}amino}-7-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-
 5 *b*]pyridazine-2-carbonitrile;
 2-methyl-*N*-[4-trifluoromethylphenyl]-7-[3-trifluoromethylpyridin-2-yl]imidazo
 [1,2-*b*]pyridazin-3-amine;
 7-[3-trifluoromethylpyridin-2-yl]-*N*-[6-trifluoromethylpyridin-3-yl]imidazo[1,2-*b*]
 pyridazin-3-amine;
 10 *N*-(4-chlorophenyl)-7-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-*b*]pyridazin-3-
 amine;
N-[2-fluoro-4-trifluoromethylphenyl]-7-[3-trifluoromethylpyridin-2-yl]imidazo
 [1,2-*b*]pyridazin-3-amine;
N-(6-methylpyridin-3-yl)-7-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-*b*]
 15 pyridazin-3-amine;
N-[4-trifluoromethoxyphenyl]-7-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-*b*]
 pyridazin-3-amine;
N-[3-fluoro-4-trifluoromethylphenyl]-7-[3-trifluoromethylpyridin-2-yl]imidazo
 [1,2-*b*]pyridazin-3-amine;
 20 7-(3-chloropyridin-2-yl)-*N*-[4-trifluoromethylphenyl]imidazo[1,2-*b*]pyridazin-3-
 amine;
N-(4-chlorophenyl)-7-(3-chloropyridin-2-yl)imidazo[1,2-*b*]pyridazin-3-amine;
 [7-(3-trifluoromethylpyridin-2-yl)-[1,2,4]triazolo[4,3-*b*][1,2,4]triazin-3-yl]-(4-
 trifluoromethylphenyl)-amine;
 25 *N*-(4-chlorophenyl)-7-[3-trifluoromethylpyridin-2-yl][1,2,4]triazolo[4,3-*b*]
 [1,2,4]triazin-3-amine;
 4-({7-[3-trifluoromethylpyridin-2-yl][1,2,4]triazolo[4,3-*b*][1,2,4]triazin-3-yl}
 amino)benzonitrile;
 7-(3-chloropyridin-2-yl)-*N*-[4-trifluoromethylphenyl][1,2,4]triazolo[4,3-*b*]
 30 [1,2,4]triazin-3-amine;
N-(4-chlorophenyl)-7-(3-chloropyridin-2-yl)[1,2,4]triazolo[4,3-*b*][1,2,4]triazin-3-
 amine;

3-(3-methylpyridin-2-yl)-*N*-[4-trifluoromethylphenyl]imidazo[1,2-*b*][1,2,4]triazin-7-amine;

3-(3-chloropyridin-2-yl)-*N*-[4-trifluoromethylphenyl]imidazo[1,2-*b*][1,2,4]triazin-7-amine;

5 *N*-[4-trifluoromethylphenyl]-3-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-*b*][1,2,4]triazin-7-amine;

N-[4-trifluoromethylphenyl]-7-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-*a*]pyridin-3-amine;

10 *N*-[4-trifluoromethylphenyl]-2-[3-trifluoromethylpyridin-2-yl]imidazo[1,5-*a*]pyrimidin-6-amine; and

N-(4-trifluoromethylphenyl)-7-(2-methoxyphenyl)[1,2,4]triazolo[4,3-*b*]pyridazine-3-amine.

Further compounds which can be converted to prodrugs of the invention include:

15 *N*-(4-fluorophenyl)-7-(3-trifluoromethylpyrid-2-yl)[1,2,4]triazolo[4,3-*b*]pyridazine-3-amine;

N-(4-acetylphenyl)-7-(3-trifluoromethylpyrid-2-yl)[1,2,4]triazolo[4,3-*b*]pyridazine-3-amine;

20 *N*-(3-trifluoromethylpyrid-4-yl)-7-(3-trifluoromethylpyrid-2-yl)[1,2,4]triazolo[4,3-*b*]pyridazine-3-amine;

N-(4-methylthiophenyl)-7-(3-trifluoromethylpyrid-2-yl)[1,2,4]triazolo[4,3-*b*]pyridazine-3-amine;

N-(1-trifluoromethylethen-1-yl)-7-(3-trifluoromethylpyrid-2-yl)[1,2,4]triazolo[4,3-*b*]pyridazine-3-amine;

25 *N*-(3-trifluoromethylpyrid-6-yl)-7-(3-trifluoromethylpyrid-2-yl)[1,2,4]triazolo[4,3-*a*]pyridine-3-amine;

N-(4-pentafluorothiophenyl)-7-(3-trifluoromethylpyrid-2-yl)[1,2,4]triazolo[4,3-*b*]pyridazine-3-amine; and

30 *N*-(4-cyanophenyl)-7-(3-trifluoromethylpyrid-2-yl)[1,2,4]triazolo[4,3-*b*]pyridazine-3-amine.

As used herein, the term "alkyl" or "alkoxy" as a group or part of a group means that the group is straight or branched. Examples of suitable alkyl groups include methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *s*-butyl and *t*-butyl. Examples of

suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy. "Alkylthio", "alkylsulfinyl" and "alkylsulfonyl" shall be construed in an analogous manner.

As used herein, the term "hydroxyC₁₋₆alkyl" means a C₁₋₆alkyl group in which one or more (in particular 1 to 3, and especially 1) hydrogen atoms have been replaced by hydroxy groups. Particularly preferred are hydroxyC₁₋₃alkyl groups, for example, CH₂OH, CH₂CH₂OH, CH(CH₃)OH or C(CH₃)₂OH, and most especially CH₂OH. "Aminoalkyl", "cyanoalkyl" and "(halo)(hydroxy)alkyl" shall be construed in an analogous manner.

As used herein, the terms "haloC₁₋₆alkyl" and "haloC₁₋₆alkoxy" means a C₁₋₆alkyl or C₁₋₆alkoxy group in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by halogen atoms, especially fluorine or chlorine atoms. Preferred are fluoroC₁₋₆alkyl and fluoroC₁₋₆alkoxy groups, in particular, fluoroC₁₋₃alkyl and fluoroC₁₋₃alkoxy groups, for example, CF₃, CH₂CH₂F, CH₂CHF₂, CH₂CF₃, OCF₃, OCH₂CH₂F, OCH₂CHF₂ or OCH₂CF₃, and most especially CF₃, OCF₃ and OCH₂CF₃.

As used herein, the terms "alkenyl" and "alkynyl" as a group or part of a group means that the group is straight or branched. Examples of suitable alkenyl groups include vinyl and allyl. A suitable alkynyl group is acetylene or propargyl.

As used herein, the term "cycloalkyl" as a group or part of a group means that the group contains a cyclic portion. Examples of suitable cycloalkyl groups include cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Cyclohexyl groups, when substituted, may have a cis or trans configuration. Terms such as "halocycloalkyl", "cyanocycloalkyl", "hydroxycycloalkyl", "aminocycloalkyl" and "(halo)(hydroxy)cycloalkyl" shall be construed analogously to the above definitions for alkyl derivatives.

When used herein, the term "halogen" means fluorine, chlorine, bromine and iodine. The most preferred halogens are fluorine and chlorine.

When used herein, the term "carboxy" as a group or part of a group denotes CO₂H.

When used herein, the term "C₁₋₆alkoxycarbonyl" denotes a C₁₋₆alkoxy or a haloC₁₋₆alkoxy radical attached via the oxygen atom thereof to a carbonyl (C=O) radical thus forming a C₁₋₆alkoxycarbonyl or haloC₁₋₆alkoxycarbonyl radical. Suitable

examples of such esterified carboxy groups include, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl and *tert*-butoxycarbonyl.

Examples of 6-membered heterocycles are pyridine, pyrimidine, pyrazine, pyridazine and triazine.

- 5 Examples of 5-membered heterocycles are thiophene, furan, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, oxadiazole, thiadiazole and tetrazole.

As used herein, the term "fused 9 or 10 membered bicyclic heteroaromatic ring system" means a 5,6-, 6,5- or 6,6-fused ring system wherein one or both rings contain
10 ring heteroatoms. The ring system is preferably aromatic or partially saturated, thus the ring system preferably comprises an aromatic 6-membered ring fused to a 5- or 6-membered ring which may be unsaturated, partially saturated or saturated. When the ring system contains more than one ring heteroatom at least one such heteroatom is nitrogen. It will be appreciated that where one of the ring heteroatoms is a nitrogen
15 atom, such heteroatom may be at the bridgehead position of the fused ring system. It will also be appreciated that where one of the ring heteroatoms in a saturated ring is sulfur, such heteroatom may be oxidized to a S(O) or S(O)₂ moiety. Likewise, any carbon atom in a saturated ring may be oxidized to a C=O moiety.

Suitable examples of a "fused 9 or 10 membered heterobicyclic ring system"
20 include isoquinolinyl, quinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, benzimidazolyl, indazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazole, pyridopyridazinyl, pyridopyrimidinyl, pyridopyrazinyl, pyrrolopyridinyl, furopyridinyl, thienopyridinyl, pyrrolopyridazinyl, furopyridazinyl,
25 thienopyridazinyl, pyrrolopyrimidinyl, furopyrimidinyl, thienopyrimidinyl, pyrrolopyrazinyl, furopyrazinyl, thienopyrazinyl, imidazopyridinyl, pyrazolopyridinyl, oxazolopyridinyl, isoxazolopyridinyl, thiazolopyridinyl, isothiazolopyridinyl, imidazopyridazinyl, pyrazolopyridazinyl, oxazolopyridazinyl, isoxazolopyridazinyl, thiazolopyridazinyl, isothiazolopyridazinyl,
30 imidazopyrimidinyl, pyrazolopyrimidinyl, oxazolopyrimidinyl, isoxazolopyrimidinyl, thiazolopyrimidinyl, isothiazolopyrimidinyl, imidazopyrazinyl, pyrazolopyrazinyl, oxazolopyrazinyl, isoxazolopyrazinyl, thiazolopyrazinyl, isothiazolopyrazinyl, triazolopyridinyl, benzotriazolyl, quinolinonyl, isoquinolinonyl, dihydroquinolinonyl,

dihydroisoquinolinonyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroquinazolinonyl, dihydrobenzoxainonyl, dihydrobenzothiadiazine oxide and dihydrobenzothiadiazine dioxide.

The pharmaceutically acceptable anion may be derived from hydrochloric acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid.

The present invention also includes within its scope N-oxides of the compounds of formula (I) above. In general, such N-oxides may be formed on any available nitrogen atom. The N-oxides may be formed by conventional means, such as reacting the compound of formula (I) with oxone in the presence of wet alumina.

The present invention includes within its scope solvates of the compounds of formula (I).

The compounds according to the invention may have one or more asymmetric centres, and may accordingly exist both as enantiomers and as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, the compounds of formula (I) may also exist in tautomeric forms and the invention includes within its scope both mixtures and separate individual tautomers.

The present invention further provides pharmaceutical compositions comprising one or more compounds of formula (I) in association with a pharmaceutically acceptable carrier or excipient.

Preferably the compositions according to the invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices, suppositories, creams or gels; for oral, parenteral, intrathecal, intranasal, sublingual, rectal or topical administration, or for administration by inhalation or insufflation. Oral compositions such as tablets, pills, capsules or wafers are particularly preferred. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to

these pre-formulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation composition is then subdivided into unit
5 dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Favoured unit dosage forms contain from 1 to 500 mg, for example 1, 5, 10, 25, 50, 100, 300 or 500 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
10 For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or
15 coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with
20 edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.

25 In the treatment of painful conditions such as those listed below, a suitable dosage level is about 1.0 mg to 15 g per day, preferably about 5.0 mg to 1 g per day, more preferably about 5 mg to 500 mg per day, especially 10 mg to 100 mg per day. The compounds may be administered on a regimen of 1 to 4 times per day.

30 It will be appreciated that the amount of a compound of formula (I) required for use in any treatment will vary not only with the particular compounds or composition selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician.

The invention further provides a compound of formula (I) as defined above for use in treatment of the human or animal body. Preferably, said treatment is for a condition which is susceptible to treatment by modulation (preferably antagonism) of VR1 receptors.

5 The compounds of the present invention will be of use in the prevention or treatment of diseases and conditions in which pain and/or inflammation predominates, including chronic and acute pain conditions. Such conditions include rheumatoid arthritis; osteoarthritis; post-surgical pain; musculo-skeletal pain, particularly after trauma; spinal pain; myofascial pain syndromes; headache, including migraine, acute
10 or chronic tension headache, cluster headache, temporomandibular pain, and maxillary sinus pain; ear pain; episiotomy pain; burns, and especially primary hyperalgesia associated therewith; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorrhoea, pain associated with cystitis and
15 labour pain, chronic pelvic pain, chronic prostatitis and endometriosis; pain associated with nerve and root damage, such as pain associated with peripheral nerve disorders, for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic douloureux, atypical facial pain, nerve root damage, and arachnoiditis; itching conditions including pruritis, itch due to hemodialysis, and
20 contact dermatitis; pain (as well as broncho-constriction and inflammation) due to exposure (e.g. via ingestion, inhalation, or eye contact) of mucous membranes to capsaicin and related irritants such as tear gas, hot peppers or pepper spray; neuropathic pain conditions such as diabetic neuropathy, chemotherapy-induced neuropathy and post-herpetic neuralgia; "non-painful" neuropathies; complex regional
25 pain syndromes; pain associated with carcinoma, often referred to as cancer pain; central nervous system pain, such as pain due to spinal cord or brain stem damage, low back pain, sciatica and ankylosing spondylitis; gout; scar pain; irritable bowel syndrome; inflammatory bowel disease; urinary incontinence including bladder detrusor hyper-reflexia and bladder hypersensitivity; respiratory diseases including
30 chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, asthma and rhinitis, including allergic rhinitis such as seasonal and perennial rhinitis, and non-allergic rhinitis; autoimmune diseases; and immunodeficiency disorders.

Thus, according to a further aspect, the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the treatment or prevention of physiological disorders that may be ameliorated by modulating VR1 activity.

5 The present invention also provides a method for the treatment or prevention of physiological disorders that may be ameliorated by modulating VR1 activity, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula (I) or a composition comprising a compound of formula (I).

10 According to a further or alternative aspect, the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates.

15 The present invention also provides a method for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula (I) or a composition comprising a compound of formula (I).

20 According to a further aspect of the present invention, it may be desirable to treat any of the aforementioned conditions with a combination of a compound according to the present invention and one or more other pharmacologically active agents suitable for the treatment of the specific condition. The compound of formula (I) and the other pharmacologically active agent(s) may be administered to a patient simultaneously, sequentially or in combination.

25 Thus, for example, for the treatment or prevention of pain and/or inflammation, a compound of the present invention may be used in conjunction with other analgesics, such as acetaminophen (paracetamol), aspirin and other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, as well as opioid analgesics, especially morphine, NR2B antagonists, bradykinin antagonists, anti-migraine agents, anticonvulsants such as oxcarbazepine and carbamazepine, antidepressants (such as TCAs, SSRIs, SNRIs, substance P antagonists, etc.), spinal blocks, gabapentin, 30 pregabalin and asthma treatments (such as β_2 -adrenergic receptor agonists or leukotriene D₄ antagonists (e.g. montelukast).


 Specific anti-inflammatory agents include diclofenac, ibuprofen, indomethacin, nabumetone, ketoprofen, naproxen, piroxicam and sulindac, etodolac,

meloxicam, rofecoxib, celecoxib, etoricoxib, parecoxib, valdecoxib and tilicoxib. Suitable opioid analgesics of use in conjunction with a compound of the present invention include morphine, codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine; or a pharmaceutically acceptable salt thereof. Suitable anti-migraine agents of use in conjunction with a compound of the present invention include CGRP-antagonists, ergotamines or 5-HT₁ agonists, especially sumatriptan, naratriptan, zolmatriptan or rizatriptan.


Therefore, in a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the present invention and an analgesic, together with at least one pharmaceutically acceptable carrier or excipient.

In a further or alternative aspect of the present invention, there is provided a product comprising a compound of the present invention and an analgesic as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a disease or condition in which pain and/or inflammation predominates.

Compounds of formula I can be made by reacting a compound of formula I' with a compound of formula XXX:




(XXX)




(I')

in which A, X, Y, Z, T¹, T², T³, T⁴, Ar, R¹, R¹⁰ and R¹¹ are as defined above, in an anhydrous solvent such as anhydrous acetonitrile, in the presence of a salt such as sodium iodide, for about 90°C for about 15 h.

Compounds of formula I' in which T³ and T⁴ are N can be made by reacting a compound of formula II with a compound of formula III:



(II)




(III)

in which Ar, R¹, R², T², X, Y and Z are as defined above and W is an isocyanate or isothiocyanate group. When W is an isocyanate group the reaction is carried out in the presence of acetonitrile with heating to about 90°C for about 12 h, followed by the addition of phosphorous oxychloride generally with heating at reflux for about 12 h, with this last step generally being repeated.

When W is an isothiocyanate group the reaction is generally heated to from 60 to 100°C for about 1 h in a solvent such as p-xylene/N,N-dimethylacetamide after which an activating agent such as dicyclohexylcarbodiimide can be added with further heating at about 100°C for about 1 h. The reaction can also be carried out in a solvent such as acetonitrile for about 15 h at about room temperature followed by heating with silver(I)acetate at about 150°C for about 10 minutes in a microwave.


Compounds of formula II in which T² is N can be made by reacting a compound of formula IV:




(IV)

in which Ar, X, Y and Z are as defined above with hydrazine, usually as its monohydrate, in a solvent such as isopropanol at about 100°C for about 15 h. This procedure can be repeated once or twice to improve yields.

Compounds of formula IV can be made by treating a compound of formula V with a compound of formula VI:



(V)




(VI)

in which Ar, X, Y and Z are as defined above and R⁴⁰ is Cl or Sn(alkyl)₃, for example Sn(methyl)₃ or Sn(n-butyl)₃. When R⁴⁰ is Cl it can be initially converted into a group B(OH)₂ under conditions suitable for a Suzuki Coupling Reaction (for review, see for instance A. Suzuki, *Pure Appl. Chem.*, 1991, **63**, 419-422), for example, in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium (0), (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium or dichloro-(1,4-bis(diphenylphosphino)butane)palladium, in a suitable solvent such as an ether, for example, dimethoxyethane or dioxane or an aromatic hydrocarbon, for example toluene, at an elevated temperature and in the presence of a base such as sodium carbonate. Where R⁴⁰ is Sn(alkyl)₃, the reaction is conveniently effected under conditions suitable for a Stille Coupling Reaction (for review, see for instance J. K. Stille, *Angew. Chem. Int. Ed.*, 1986, **25**, 508-524), for example, in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium (0) or bis(triphenylphosphine)palladium (II) chloride, in a suitable solvent such as an ether, for example dioxane, or an aromatic hydrocarbon, for example, toluene, at an elevated temperature, and in the presence of catalysts such as LiCl and CuI.

The resulting compound can be converted to the desired chloride IV by reacting with phosphorous oxychloride at about 100°C for about 1 h.


Alternatively compounds of formula IV can be made by reacting a compound of formula ArH with a compound of formula X:



(X)

in which X, Y and Z are as defined above and V is a protecting group such as tetrahydropyranyl. The reaction is generally carried in the presence of a strong base such as BuLi, in the presence of zinc chloride and catalyst such as $\text{Pd(PPh}_3)_4$ in a solvent such as tetrahydrofuran between about -78°C and room temperature for about 2 h. The resulting product can be deprotected using phosphorous oxychloride with heating to about 90°C for about 10 min.

Compounds of formula II in which T^2 is $\text{C(CH}_2)_n\text{R}^2$ can be made by reacting a compound of formula VII:




(VII)

in which n, Ar, X, Y and Z are as defined above with ammonia in a hydrogenating environment, such as $\text{H}_2/\text{Pd/C}$, generally in a solvent such as methanol at about room temperature for about 1 h.


The nitrile of formula VII can be made by reacting the corresponding amide with a dehydrating agent such as Burgess reagent for up to 6 h in a solvent such as dichloromethane. This amide can be made from the corresponding carboxylic acid ester which is reacted with ammonia in a solvent such as methanol for about 3 h.

This carboxylic acid ethyl ester can be made from the corresponding compound of formula IV under an atmosphere of carbon monoxide in ethanol in the presence of a palladium catalyst such as $\text{Pd(dppf)Cl}_2 \cdot \text{CHCl}_3$ and a base such as sodium acetate at about 90°C for about 2 h.

In an alternative route, compounds of formula I can be made by reacting a compound of formula VIII with a compound of formula IX:



(VIII)




(IX)

in which T^1 , T^2 , T^3 , T^4 , X, Y, Z, Ar and R^1 are as defined above and Hal is bromine or iodine. The reaction is generally carried out in the presence of a catalyst such as tris(dibenzylidene)dipalladium together with cesium carbonate in a solvent such as 1,4-dioxane at about 100°C for from 15 min to 18 h. The reaction is promoted using a catalyst such as xantphos.

The compound of formula VIII can be made by reducing the corresponding nitro compound with, for example, Lindlar catalyst in MeOH:EtOAc on a Parr hydrogenator under H_2 for about 30 min.

This nitro compound can be made by nitrating a compound of formula XI:




(XI)

in which T^1 , T^2 , T^3 , T^4 , X, Y, Z and Ar are as defined above with, for example, a mixture of concentrated H_2SO_4 and fuming HNO_3 for about 30 min at about 0°C .

Compounds of formula XI in which T^2 and T^4 are N and T^3 is $\text{C}(\text{CH}_2)_n\text{R}^2$ can be made by reacting a compound of formula XVII with bromoacetaldehyde or chloroacetaldehyde in a solvent such as ethanol in the presence of a mild base such as sodium hydrogencarbonate at about reflux for about 18 h. Bromoacetaldehyde can be made in situ by reacting bromoacetaldehydedimethylacetal with an acid such as hydrobromic acid in a solvent such as water.


The compound of formula XI can also be made by reacting a compound of formula V with a compound of formula XII:




(XII)

in which X, Y, Z, T¹, T², T³ and T⁴ are as defined above by a Suzuki reaction as
 5 described above, for example using bispinacolatodiborane.

Compounds of formula XII in which T¹=T²=X=N, T³=C(CH₂)_nR² and
 Y=Z=C(CH₂)_nR³ can be made by reacting a compound of formula XIII with a
 compound of formula XIV:



(XIII)




(XIV)

in which n, R² and R³ are as defined above, in the presence of acetic acid and in a
 solvent such as ethanol for about 4 h at reflux.

Compounds of formula XI can also be made by ring-closing a compound of
 15 formula II with, for example, formic acid at about 80°C for about 30 min.

Compounds of formula VIII in which T²=T³=T⁴=N can be made by reacting a
 compound of formula IV with thiosemicarbazide generally in glacial acetic acid at
 about 135°C for about 12 h.


An alternative route to producing compounds of formula IV in which X=N,
 20 Y=CCl and Z=CH is provided by reacting a compound of formula XV:



(XV)

in which Ar is as defined above successively with hydrazine monohydrate and phosphorous oxychloride. The former reaction is generally carried out in glacial acetic acid with the gradual addition of concentrated sulphuric acid followed by heating to about 125°C for about 3 h.


The compound of formula XV can be made by reacting a compound of formula XVI:



(XVI)

in which Ar is as defined above with glyoxylic acid monohydrate in a solvent such as methanol in the presence of a base such as potassium carbonate for about 15 h at about room temperature, followed by reacting with a mixture of formic acid and sulphuric acid generally at reflux for about 3 h.

Compounds of formula XI in which $T^2=T^4=N$ and $T^3=CH$ can be made by reacting a compound of formula XVII:




(XVII)

in which Ar, X, Y and Z are as defined above with chloroacetaldehyde generally in a solvent such as ethanol in the presence of a base such as sodium bicarbonate at reflux for about 18 h. Compounds of formula XVII can also be made by reacting a

compound of formula XVIII with ammonia generally in a solvent such as water in a microwave at about 140°C for about 30 minutes.

5 The compound of formula XVII can be made by reducing a compound of formula II in which T² is N for example with Raney Nickel under H₂ at about room temperature for about 48 h.

In an alternative method compounds of formula II can be made by reacting a compound of formula XVIII:




(XVIII)

10

in which Ar, X, Y and Z are as defined above with hydrazine monohydrate in a solvent such as ethanol at reflux for about 16 h.

Compounds of formula XVIII in which X=Z=N and Y=CH can be made by reacting a compound of formula XIX:


15



(XIX)

20 in which Ar is as defined above with aminomethanehydrazonathionate, generally as the hydroiodide salt, in a solvent such as water between about 0°C and room temperature for about 1 h.

Compounds of formula I can also be made by reacting a compound of formula XX with a compound of formula XXI:



(XX)



(XXI)

wherein T¹, T², T³, T⁴, X, Y, Z, Ar and R¹ are as defined above. The reaction is generally carried out in a solvent such as dioxane in the presence of an acid catalyst
 5 such as hydrobromic acid for about 15 min in a microwave.

The compound of formula XX can be made by brominating a compound of formula XI, for example using bromine in the presence of a buffered solution such as a mixture of acetic acid and sodium acetate at about 120°C for about 2 h.

Compounds of formula I can be converted to other compounds of formula I by
 10 methods known in the art. Indeed, any of the intermediates can be functionalised by conventional methods. For example, compounds having an R³ group which is chlorine can be converted to compounds where that R³ group is hydrogen by reacting with ammonium formate in the presence of a catalyst such as Pd/C in a solvent such as anhydrous ethanol at about 80°C for about 15 h.

15 Compounds in which Ar or Ar¹ is substituted by bromine can be converted into compounds where Ar or Ar¹ is substituted by an aromatic group by performing the appropriate Stille Coupling Reaction as described above.

Compounds having an acetyl group can be reacted with a methylating agent such as methyl magnesium bromide in a solvent such as tetrahydrofuran at a
 20 temperature of from -40°C to 0°C for about 15 h to produce the 2-hydroxyprop-2-yl analogue. Compounds in which the nitrogen atom of a pyridine moiety is oxidized can be made by reacting with, for example, oxone in a solvent such as chloroform in the presence of a catalyst such as aluminium oxide generally at reflux for about 18 h.

Compounds of formula I' in which R² is H can be brominated to compounds of
 25 formula I' in which R² is Br by reacting with a brominating agent such as N-bromosuccinimide in a solvent such as dichloromethane for about 5 min at about room temperature. This compound can undergo Suzuki Coupling Reactions to compounds of formula I in which R² is an aromatic group. The bromine atom can be

replaced by a cyano group by reacting with zinc cyanide in the presence of a catalyst such as zinc powder and a coupling agent such as

[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane complex in a solvent such as N,N-dimethylacetamide at about 160°C for about 20 min

5 in a microwave. The cyano group can be converted to a formamide residue by hydrolyzing with, for example, concentrated hydrochloric acid at about 80°C for about 20 min in a microwave. Compounds in which n in $(CH_2)_nR^2$ is one and where R^2 is

bound to the methylene group via a nitrogen atom, can be made by reacting a

10 compound of formula I' in which R^2 is hydrogen with formaldehyde and the nitrogen containing moiety, such as morpholine or dimethylamine, in the presence of an acid, such as acetic acid, in a solvent such as water at about room temperature for from 20

to 24 h. Compounds of formula I' in which R^2 is carboxy can be made from

compounds of formula I' in which R^2 is bromine by reacting with carbon monoxide in ethanol in the presence of sodium acetate and a coupling agent such as

15 [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane complex at about reflux for about 3 h followed by hydrolysing the ester for example in a mixture of methanol, water and tetrahydrofuran in the presence of a base such as lithium hydroxide at about room temperature for about 24 h.

Intermediates for which no preparation is described above are commercially
20 available or can be made from commercially available compounds by methods known in the art. The preparation of some of these intermediates is provided in the Descriptions and Examples.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned.

25 This may be achieved by means of conventional protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

30 The following Examples serve to illustrate the preparation of compounds of the present invention.

COMMON INTERMEDIATES

Description 1

3-Chloro-5-(3-trifluoromethyl-2-pyridyl)pyridazine

To a mixture of 5-chloropyridazin-3-one (8.6g, 62.9 mmol) and
5 bis(pinacolato)diboron (16.8 g, 66.2 mmol) in anhydrous 1,4-dioxane (100 ml) was
added bis(diphenylphosphino)ferrocenylpalladiumdichloride (2.3 g, 3.1 mmol) and
potassium acetate (18.5 g, 188.5 mmol) and nitrogen was bubbled through the mixture
for 10 min. The mixture was heated at 100°C for 15 h, allowed to cool to room
temperature and a mixture of 2-chloro-3-(trifluoromethyl)pyridine (10.9g, 60 mmol)
10 and bis(diphenylphosphino)ferrocenylpalladiumdichloride (2.3 g, 3.1 mmol) followed
by 2M sodium carbonate (100 ml) was added to the black mixture and nitrogen was
bubbled through for 10 min. The resulting mixture was heated at 100 °C for 15 h,
allowed to cool to room temperature and poured into a mixture of ethyl acetate/
ethanol/ water (500/ 100/ 100 ml). The phases were separated and the aqueous phase
15 was extracted two times with ethyl acetate (200 ml each). The combined organic
layers were washed with brine, dried over sodium sulfate and adsorbed onto silica gel.
Purification by flash chromatography (ethyl acetate) gave 5-(3-trifluoromethyl-2-
pyridyl)pyridazin-3-one (4.9 g, 32 %) as an off white solid, MS: (ES (M+1)) 242.
The pyridazinone (4.8 g, 20 mmol) was suspended in phosphorous oxychloride (30
20 ml, 322 mmol) and the mixture was heated at 100°C for 1 h. After cooling to room
temperature the homogeneous dark solution was evaporated under reduced pressure
and repartitioned between chloroform and water (50 ml each). The pH was adjusted to
8 by portionwise addition of saturated aqueous sodium carbonate solution and the
phases were separated. After two further extractions the combined organic extracts
25 were washed with water and brine and dried over sodium sulfate. After filtration the
compound was adsorbed onto silica gel and purified by flash column (50% ethyl
acetate-iso-hexane) to yield the title compound (3.9 g, 75 %), MS: (ES (M+1))
260/262.

¹H NMR (360 MHz, DMSO) δ 7.85 (1H, dd, *J* = 7.5 and 4.5), 8.16 (1H, d, *J* = 1.5),
30 8.45 (1H, d, *J* = 7.5), 9.02 (1H, d, *J* = 4.5), 9.43 (1H, d, *J* = 1.5) ppm.

Description 2N-(4-Trifluoromethylphenyl)-7-(3-trifluoromethyl-2-pyridyl)[1,2,4]triazolo[4,3-b]pyridazine-3-amine

To a mixture of Description 1 (3.5 g, 13.8 mmol) in anhydrous isopropanol (20 ml) was added hydrazine monohydrate (3.4 ml, 70 mmol) and the mixture was heated at 100°C for 15 h. After cooling to room temperature the solution was concentrated under reduced pressure and toluene was added to the resulting oil. The mixture was concentrated under reduced pressure again and the whole procedure was repeated twice to yield 3-hydrazino-5-(3-trifluoromethyl-2-pyridyl)pyridazine (3.2 g, 91 %) as a red syrup which crystallises over 3 days at room temperature.

The pyridazine (0.56 g, 2.2 mmol) was dissolved in dry acetonitrile (10 ml) and a solution of 4-trifluoromethylphenylisocyanate (0.43 g, 2.3 mmol) in 3 ml acetonitrile was added dropwise while stirring at room temperature. The solution was heated at 90°C for 12 h and cooled to room temperature. Phosphorous oxychloride (0.41 ml, 4.4 mmol) was added dropwise to the suspension and the resulting mixture was heated under reflux for 12 h. After addition of more phosphorous oxychloride (0.41 ml, 4.4 mmol) the mixture was heated for another 12 h under reflux and tlc showed complete conversion of starting material. The resulting yellow solution was poured onto a mixture of chloroform and water (200/ 20 ml) and the pH was adjusted to 8 by portionwise addition of saturated aqueous sodium carbonate solution and the phases were separated. After two further extractions the combined organic extracts were washed with water and brine and dried over sodium sulfate. After filtration the compound was adsorbed onto silica gel and purified by flash column (50% ethyl acetate) to yield the title compound (0.45 g, 48 %) as a canary-yellow solid, MS: (ES (M+1)) 425.

¹H NMR (360 MHz, DMSO) δ 7.70 (2H, d, *J* = 8.7), 7.81 (1H, dd, *J* = 8.0 and 4.6), 8.07 (2H, d, *J* = 8.7), 8.37 (1H, d, *J* = 1.4), 8.45 (1H, d, *J* = 8.0), 8.77 (1H, d, *J* = 1.4), 9.03 (1H, d, *J* = 4.6), 10.32 (1H, s) ppm.

Description 35-[3-Trifluoromethylpyridin-2-yl]pyridazin-3-amine

Raney Nickel (50% aq. suspension, 2 ml) was added to a solution of 3-hydrazino-5-[3-trifluoromethylpyridin-2-yl]pyridazine (from Description 2; 1.10 g, 4.31 mmol) in

ethanol (100 ml). The mixture was then stirred under a balloon of hydrogen gas for 48 h. The catalyst was then filtered off on a glass fibre pad, washing the solid thoroughly with ethanol. The filtrate was evaporated and the residue was then purified using a strong cation exchange (SCX) ion exchange cartridge washing away non-basic impurities with methanol, then eluting with 2M methanolic ammonia solution. Evaporation of the basic fraction gave the title compound as a red-brown solid (573 mg). ¹H NMR (400 MHz, DMSO) δ 8.97 (1H, br. d, *J* 5), 8.48 (1H, d, *J* 2), 8.37 (1H, d, *J* 8), 7.75 (1H, dd, *J* 8, 5), 6.82 (1H, d, *J* 2), 6.60 (2H, br. s); *m/z* (ES⁺) 241 (M + H⁺).

10

Description 4

7-[3-Trifluoromethylpyridin-2-yl]imidazo[1,2-*b*]pyridazine

Description 3 (570 mg, 2.38 mmol) was dissolved in ethanol (10 ml). Sodium bicarbonate (400 mg, 4.75 mmol) was then added followed by chloroacetaldehyde (45% aq. solution, 450 µl, ca. 3.25 mmol) and the reaction mixture was heated at reflux for 18 h. After cooling to room temperature, flash silica was added, the solvent removed and the residue purified by flash column chromatography (eluant 1:19 MeOH-CH₂Cl₂) to give the title compound. ¹H NMR (400 MHz, DMSO) δ 9.01 (1H, d, *J* 5), 8.68 (1H, d, *J* 2), 8.44 (1H, br. s), 8.42 (1H, d, *J* 8), 8.25 (1H, br. s), 7.93 (1H, s) 7.78 (1H, dd, *J* 8, 5); *m/z* (ES⁺) 265 (M + H⁺).

20

Description 5

3-Nitro-7-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-*b*]pyridazine

Description 4 (337 mg, 1.28 mmol) was dissolved in conc. sulfuric acid (3 ml) at 0°C. A nitrating mixture of conc. sulfuric acid and fuming nitric acid (1:1, 2 ml) was then added dropwise over 10 min. The mixture was then allowed to warm to room temperature and stir for 20 h before pouring into ice-water (150 ml). The mixture was made basic by addition of 33 % aqueous ammonia solution, then extracted with ethyl acetate (3 x 30 ml). The combined organic layers were dried (Na₂SO₄) and evaporated and the residue purified by flash column chromatography (eluant 1:19 MeOH-CH₂Cl₂) to give the title compound (240 mg) as a colourless solid. ¹H NMR (400

30

MHz, DMSO) δ 9.14 (1H, d, J 2), 9.06 (1H, d, J 5), 8.93 (1H, s), 8.2 (1H, d, J 2), 8.47 (1H, d, J 8), 7.84 (1H, dd, J 8, 5); m/z (ES^+) 310 ($M + H^+$).

Description 6

5 7-[3-Trifluoromethylpyridin-2-yl]imidazo[1,2-*b*]pyridazin-3-amine

Lindlar catalyst (100 mg) slurried in ethanol (1 ml) was added to a solution of Description 5 (170 mg, 0.55 mmol) in an ethanol - ethyl acetate mixture (1:1, 10 ml). The reaction mixture was then stirred under a balloon of hydrogen gas at room temperature for 5 h. The mixture was then filtered, washing the catalyst with ethanol (5 ml) and the filtrate was then evaporated. Addition of toluene (5 ml) to the residue and re-evaporation gave the title compound (153 mg) as a red oil which was free of ethanol and used without further purification. 1H NMR (500 MHz, DMSO) δ 8.98 (1H, d, J 5), 8.54 (1H, s), 8.38 (1H, d, J 8), 7.96 (1H, s), 7.71 (1H, dd, J 8, 5), 7.21 (1H, s), 5.74 (2H, s); m/z (ES^+) 280 ($M + H^+$).

15

Description 7

N-[4-Trifluoromethylphenyl]-7-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-*b*]pyridazin-3-amine

A mixture of Description 6 (150 mg, 0.55 mmol), 4-bromobenzotrifluoride (125 mg, 77 μ l, 0.55 mmol) and caesium carbonate (254 mg, 0.78 mmol) in 1,4-dioxan (5 ml) was degassed ($N_2 \times 3$), then 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene [xantphos] (19.3 mg, 0.033 mmol) and tris(dibenzylideneacetone)dipalladium (0) (10.2 mg, 0.011 mmol) were added and the mixture degassed again ($N_2 \times 3$). The reaction was then heated to 100°C for 24 h under nitrogen, then cooled to room temperature and diluted with tetrahydrofuran (20 ml). The mixture was then filtered through a glass fibre pad and the filtrate evaporated. The residue was purified by flash column chromatography (eluant 1:39 MeOH- CH_2Cl_2) and also by mass-directed preparative hplc to give the title compound as a yellow-orange solid (115 mg). 1H NMR (500 MHz, DMSO) δ 9.06 (1H, s), 9.02 (1H, d, J 5 Hz), 8.70 (1H, d, J 1.5 Hz), 8.43 (1H, d, J 8 Hz), 8.24 (1H, d, J 1.5 Hz), 7.94 (1H, s), 7.78 (1H, dd, J 8, 5 Hz), 7.53 (2H, d, J 8 Hz), 6.96 (2H, d, J 8 Hz); MS: (ES ($M+1$)), 424.

30

Description 8

5-(3-Trifluoromethylpyridin-2-yl)pyridazine-3-carboxylic acid ethyl ester

To a solution of Description 1 (0.50 g, 1.93 mmol) in ethanol in a 3-neck flask equipped with a condenser and a bubbler was added sodium acetate (0.32 g, 3.86 mmol). Nitrogen was bubbled through the resulting solution for 10 min. Pd(dppf)Cl₂.CHCl₃ (0.10 g, 0.14 mmol) was added and the reaction flushed with carbon monoxide. After 5 min of rapid CO bubbling the orange solution had darkened. The gas flow rate was reduced and the reaction heated to 90° C. After 2 h the starting material had been consumed and the solution was flushed with nitrogen. The reaction was condensed, partitioned between pH 7 phosphate buffer and ethyl acetate and the aqueous layer washed again with ethyl acetate. The organic layers were combined, dried over MgSO₄ and the crude product purified by flash column chromatography, eluting with 50 % to 25 % hexane in ethyl acetate to give the ethyl ester (0.37 g, 66 %). *m/z* (ES⁺) 297 (M + H⁺). ¹H NMR (400 MHz, CDCl₃) 1.51 (3H, t, *J* 7.1), 4.59 (2H, q, *J* 7.1), 7.63 (1H, m), 8.20 (1H, dd, *J* 8.1, 0.8), 8.38 (1H, d, *J* 2.1), 8.96 (1H, d, *J* 0.7), 9.51 (1H, d, *J* 2.1).

Description 9

5-(3-Trifluoromethylpyridin-2-yl)pyridazine-3-carboxylic acid amide

To Description 8 (150 mg) was added a solution of ammonia in methanol (2 M, 10 ml) and the reaction stirred for 3 h. The reaction was condensed to yield the desired amide (140 mg, 100 %). *m/z* (ES⁺) 269 (M + H⁺). ¹H NMR (400 MHz, CDCl₃) 5.96 (1H, s), 7.61 (1H, ddd, *J* 7.8, 4.7, 0.9), 8.07 (1H, s), 8.19 (1H, dd, *J* 7.9, 1.0), 8.50 (1H, d, *J* 2.2), 8.96 (1H, d, *J* 5.0), 9.47 (1H, d, *J* 2.2).

Description 10

4-Trifluoromethylphenyl-3-(3-trifluoromethylpyridin-2-yl)imidazo[1,5-*b*]pyridazin-7-ylamine

To a solution of Description 9 (5 mg) in dichloromethane (0.5 ml) was added Burgess reagent (9 mg) in 3 portions over 1 h. After 3 h an additional 3 mg Burgess reagent added. After 6 h the reaction was condensed and the product isolated by gradient column chromatography, eluting with 50 % ethyl acetate in hexane- neat ethyl acetate to give the desired nitrile (4 mg). ¹H NMR (400 MHz, CDCl₃) 7.59 (1H, ddd, *J* 8.2,

4.1, 1.3 Hz), 7.95 (1H, d, *J* 2.2 Hz), 8.15 (1H, dd, *J* 8.0, 1.0 Hz), 8.91 (1H, s), 9.48 (1H, d, *J* 2.2 Hz). The nitrile (4 mg) was taken up in a solution of ammonia in methanol (2 M, 0.75 ml). 2 drops of a slurry of 10 % Pd/C in water were added and the reaction stirred under a balloon of hydrogen. After 1 h the product had been consumed and the reaction was filtered and the filtrate condensed in vacuo. The crude amine was taken up in toluene (1 ml) and 4-trifluoromethyl phenylisothiocyanate (4 mg) was added and the reaction stirred at room temperature for 2 h. A further isothiocyanate (1 mg) was added and the reaction stirred an additional 90 min. Dicyclohexylcarbodiimide (4 mg) was added and the reaction heated to 100°C. After 45 min the reaction was condensed and purified by gradient column chromatography, eluting with 3:1 to 1:1 hexane:ethyl acetate followed SCX column chromatography eluting with methanol then ammonia in methanol (2M) to give the desired imidazopyridizine (2.75 mg). MS: (ES (M+1)), 424 ¹H NMR (500 MHz, MeOH-d₄) 7.46 (1H, s), 7.57 (2H, d, *J* 8.6 Hz), 7.65 (1H, ddd, *J* 8.1, 4.9, 0.8 Hz), 7.76 (2H, d, *J* 8.5 Hz), 8.04 (1H, d, *J* 2.1 Hz), 8.27 (1H, d, *J* 2.2 Hz), 8.30 (1H, dd, *J* 8.1, 1.3 Hz), 8.90 (1H, s).

FINAL PRODUCTS

20

Example 1

5-(2,2-Dimethylpropanoyloxymethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride

To a mixture of Description 2 (0.712 g, 1.68 mmol) in anhydrous acetonitrile (10 ml) was added chloromethyl pivalate (1.22 ml, 8.40 mmol) and sodium iodide (25 mg, 0.17 mmol) and the mixture was heated at 90 °C for 15 hours. After cooling to room temperature the solution was concentrated under reduced pressure and diethyl ether (10 ml) was added to the resulting brown gum to induce crystallisation. The resulting solid was filtered and washed with additional diethyl ether and dried on the sinter to yield a brown solid which was dissolved in dimethylsulfoxide and submitted to reverse phase HPLC purification (using aqueous diethylamine/ acetonitrile gradients). The purple product fractions were combined and evaporated to dryness under reduced pressure to yield 375 mg of a purple solid which was dissolved in acetonitrile (5 ml) and a solution of 1 M hydrogen chloride in diethyl ether was added until the colour

changed from purple to bright yellow (0.7 ml; 0.7 mmol). Diethyl ether was added (5 ml) to induce crystallization and the yellow product was filtered and washed with diethyl ether (5 ml) and dried on the sinter to yield the target compound (0.36 g; 37 %) as a bright yellow solid, MS: (ES (M+)) 539. ¹H NMR (360 MHz, DMSO) δ 1.17 (9H, s), 6.60 (2H, s), 7.85 (2H, d, *J* = 8.7), 7.95 (1H, dd, *J* = 8.0 and 4.6), 8.01 (2H, d, *J* = 8.7), 8.58 (1H, d, *J* = 8.0), 9.14 (1H, d, *J* = 4.6), 9.17 (1H, d, *J* = 1.6), 9.49 (1H, d, *J* = 1.6), 11.46 (1H, s) ppm.

Example 2

10 5-(1-(2,2-Dimethylpropanoyloxy)-1-ethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride

A procedure analogous to that of Example 1 gave the target compound (0.045 g, 25 %) as a bright yellow solid, MS: (ES (M+)) 553. ¹H NMR (500 MHz, DMSO) δ 1.15 (9H, s), 1.92 (3H, d, *J* = 6.0), 7.47 (1H, q, *J* = 6.0), 7.85 (2H, d, *J* = 8.0), 7.97 (1H, dd, *J* = 8.0 and 4.6), 8.01 (2H, d, *J* = 8.6), 8.57 (1H, d, *J* = 8.0), 9.13 (2H, m), 9.45 (1H, d, *J* = 1.3), 11.42 (1H, s) ppm.

Example 3

20 5-(1-Acetoxy-1-ethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride

A procedure analogous to that of Example 1 gave the target compound (0.038 g, 20 %) as a bright yellow solid, MS: (ES (M+)) 511. ¹H NMR (500 MHz, DMSO) δ 1.92 (3H, d, *J* = 6.0), 2.07 (3H, s), 7.52 (1H, q, *J* = 6.0), 7.85 (2H, d, *J* = 7.9), 7.95 (1H, m), 8.03 (2H, d, *J* = 7.9), 8.57 (1H, d, *J* = 8.3), 9.13 (2H, m), 9.45 (1H, s), 11.43 (1H, s) 25 ppm.

Example 4

30 5-(2-Methylpropanoyloxymethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride

A procedure analogous to that of Example 1 gave the target compound (0.065 g, 37 %) as a bright yellow solid, MS: (ES (M+)) 525. ¹H NMR (500 MHz, DMSO) δ 1.11 (6H, d, *J* = 7.0), 2.64 (1H, q, *J* = 7.0), 6.61 (2H, s), 7.85 (2H, d, *J* = 8.7), 7.96 (1H, dd,

$J = 8.0$ and 5.0), 8.02 (2H, d, $J = 8.7$), 8.57 (1H, d, $J = 8.0$), 9.14 (1H, d, $J = 5.0$), 9.18 (1H, d, $J = 1.5$), 9.48 (1H, d, $J = 1.5$), 11.48 (1H, s) ppm.

Example 5

5 5-(1-Pyrrolidinylcarbonyloxymethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride

A procedure analogous to that of Example 1 gave the target compound (0.13 g, 42 %) as a bright yellow solid, MS: (ES (M⁺)) 552. ¹H NMR (500 MHz, DMSO) δ 1.79 (4H, m), 3.24 (2H, t, $J = 6.6$), 3.35 (2H, t, $J = 6.6$), 6.55 (2H, s), 7.85 (2H, d, $J = 8.7$),
10 7.95 (1H, dd, $J = 8.0$ and 5.1), 8.03 (2H, d, $J = 8.7$), 8.57 (1H, d, $J = 8.0$), 9.12 (1H, d, $J = 1.5$), 9.15 (1H, d, $J = 5.1$), 9.45 (1H, d, $J = 1.5$), 11.42 (1H, s) ppm.

Example 6

15 5-(1-(2-Methylpropanoyloxy)-1-ethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride

A procedure analogous to that of Example 1 gave the target compound (0.135 g, 48 %) as a bright yellow solid, MS: (ES (M⁺)) 539. ¹H NMR (500 MHz, DMSO) δ 1.05 (3H, d, $J = 7.0$), 1.12 (3H, d, $J = 7.0$), 1.92 (3H, d, $J = 6.0$), 2.60 (1H, sept, $J = 7.0$), 7.50 (1H, q, $J = 6.0$), 7.84 (2H, d, $J = 8.7$), 7.96 (1H, dd, $J = 8.0$ and 5.0), 8.03 (2H, d, $J = 8.7$), 8.57 (1H, d, $J = 8.0$), 9.14 (2H, m), 9.45 (1H, d, $J = 1.5$), 11.44 (1H, s) ppm.

Example 7

25 5-(1-(1-Methyl-1-ethoxycarbonyloxy)-1-ethyl)-3-(4-trifluoromethylphenylamino)-7-(3-trifluoromethyl-2-pyridyl)-[1,2,4]triazolo[4,3-b]pyridazinium chloride

A procedure analogous to that of Example 1 gave the target compound (0.14 g, 39 %) as a bright yellow solid, MS: (ES (M⁺)) 555. ¹H NMR (500 MHz, DMSO) δ 1.17 (3H, d, $J = 6.3$), 1.24 (3H, d, $J = 6.3$), 1.94 (3H, d, $J = 6.0$), 4.74 (1H, sept, $J = 6.3$), 7.46 (1H, q, $J = 6.0$), 7.85 (2H, d, $J = 8.7$), 7.96 (1H, dd, $J = 8.1$ and 5.0), 8.05 (2H, d, $J = 8.7$), 8.57 (1H, d, $J = 8.1$), 9.13 (1H, d, $J = 1.5$), 9.16 (1H, d, $J = 5.0$), 9.46 (1H, d, $J = 1.5$), 11.49 (1H, s) ppm.

Example 8

1-{[2,2-Dimethylpropanoyloxy]methyl}-3-{4-trifluoromethylphenylamino}-7-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-*b*]pyridazin-1-ium chloride

A procedure analogous to that of Example 1 using Description 7 gave the target compound (0.07 g, 23 %) as a bright yellow solid, MS: (ES (M⁺)) 538. ¹H NMR (500 MHz, DMSO) δ 1.17 (9H, s), 6.50 (2H, s), 7.22 (2H, d, *J* = 8.5), 7.63 (2H, d, *J* = 8.7), 7.92 (1H, dd, *J* = 4.9, 8.1), 8.54 (1H, d, *J* = 8.1), 8.76 (1H, s), 9.10 (1H, d, *J* = 4.5), 9.17 (1H, d, *J* = 1.8), 9.37 (1H, d, *J* = 1.7), 9.74 (1H, s).

Example 9

6-{[2,2-Dimethylpropanoyloxy]methyl}-7-{4-trifluoromethylphenylamino}-3-[3-trifluoromethylpyridin-2-yl]imidazo[1,5-*b*]pyridazin-6-ium chloride

A procedure analogous to that of Example 1 using Description 10 gave the target compound (0.06 g, 20 %) as a yellow solid, MS: (ES (M⁺)) 538.

Biological Methodology

Determination of *in vitro* activity

CHO cells, stably expressing recombinant human VR1 receptors and plated into black-sided 384-well plates, were washed twice with assay buffer (Hepes-buffered saline) and then incubated with 1 μM Fluo-3-AM for 60 minutes in darkness. Cells were washed twice more to remove excess dye, before being placed, along with plates containing capsaicin and test compounds in a Molecular Devices FLIPR. The FLIPR simultaneously performed automated pharmacological additions and recorded fluorescence emission from Fluo-3. In all experiments, basal fluorescence was recorded, before addition of test compounds and subsequent addition of a previously determined concentration of capsaicin that evoked 80% of the maximum response. Inhibition of capsaicin evoked increases in intracellular [Ca²⁺] were expressed relative to wells on the same plate to which capsaicin was added in the absence of test compounds. Increases in intracellular [Ca²⁺] occurring after addition of test compound alone, prior to addition of capsaicin, allow determination of intrinsic agonist or partial agonist activity, if present. All the above compounds had an IC₅₀ of below 2 μM.

Determination of *in vivo* efficacy in a capsaicin paw flinch model

(Method adapted from Taniguchi *et al*, 1997, *Br J Pharmacol.* **122**(5):809-12)

To determine *in vivo* functional occupancy of VR1 receptors, compounds are administered orally to male Sprague Dawley rats typically 1 hour prior to receiving an intraplantar injection of capsaicin (2Tg dissolved in ethanol) and the number of
5 flinches of the injected paw is recorded for 5 minutes immediately thereafter. Statistical analysis is performed using one-way ANOVA followed by Dunnett's test; p values <0.05 compared to capsaicin/vehicle-treated rats are considered significant.

10 Determination of *in vivo* efficacy in a model of inflammatory pain

(Method adapted from Hargreaves *et al*, 1988 *Pain*, **32**(1):77-88).

Antinociceptive activity is determined using a rat carrageenan-induced thermal hyperalgesia assay. Inflammatory hyperalgesia is induced by intraplantar injection of carrageenan (lambda-carrageenan 0.1 ml of 1% solution made up in saline) into one
15 hind paw. Compounds are given orally typically 2 hours after carrageenan and paw withdrawal latencies determined 1 hour later. Paw withdrawal latencies to application of noxious thermal stimuli to plantar surface of the hind paw are measured using the Hargreaves apparatus. Thermal hyperalgesia is defined as the difference in paw withdrawal latencies for saline/vehicle- and carrageenan/vehicle-treated rats. Paw
20 withdrawal latencies for drug treated rats are expressed as a percentage of this response. Statistical analysis is performed using one-way ANOVA followed by Dunnett's test; p values <0.05 compared to carrageenan/vehicle-treated rats are considered significant.

